Researchers from the TxCell company in Valbonne (France) have developed a new cell therapy for chronic inflammatory disorders such as Crohn's disease that shows promising results in the first clinical trials that evaluate it. The scientific work has been made public during the annual meeting of the National Stem Cell Network of the United Kingdom held in Nottingham.
The scientists presented their research on a new cell therapy aimed at the treatment of chronic inflammatory disorders such as Crohn's disease. In the study they used patients' blood cells to produce a type of cell, the T-type 1 regulatory lymphocyte, which can reduce the extent of the disease.
According to Miguel Forte, responsible for the study, "T-regulatory lymphocytes are amazing cells, they secrete proteins called cytokines that slow down the excessive immune response that causes the terrible symptoms of chronic inflammatory diseases like Crohn's .. We know that treatments based on these cells work, but the challenge is to develop them in the clinic To maximize the benefits and minimize the risks, we must show that these cells are well tolerated and do a good job to treat the disease. ".
Researchers have used cells from the patient's immune system derived from a type of blood cell (PBMCs) to treat patients with diseases such as Crohn's. They obtained these cells from patients with Crohn's disease, who had been previously treated with drugs or surgery, and still had significant symptoms due to resistance to treatment, to produce type 1 regulatory T lymphocytes, which were then returned to the patient.
The purpose of the study was to assess how well patients generally responded to the new treatment as well as to determine the efficacy of these cells in improving Crohn's disease. The preliminary results show a good tolerability and it has been proven that, when the correct dose is given, patients with severe Crohn's disease who do not respond to other treatments get an improvement.
Cell therapy methods such as this use live cells to perform innovative treatments that can meet medical needs that have not been resolved by conventional treatment.
"It's still early, but the preliminary results are very good, the treatment did not make patients sick in any way, and there is an initial indication that Crohn's disease improved, and the next step is to do a clinical trial to find out if the treatment really It works, in what types of chronic inflammatory disease, and learn more about possible side effects and how to control them, to confirm our results on the best dose to use ", concludes Forte.
Source: EUROPE PRESS